Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 88 • 2019 ACR/ARP Annual Meeting
Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets
Irene Cecchi¹, Massimo Radin ¹, Elena Rubini ¹, Silvia Grazietta Foddai ¹, Ana Suarez ², Elisa Menegatti ¹, Dario Roccatello ¹, Savino Sciascia ³ and Javier Rodriguez Carrio ², ¹University of Turin, Turin, Italy, ²University of Oviedo, Oviedo, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: Type I Interferons (IFN) play a key role in the pathogenesis and evolution of various autoimmune diseases. Previous studies have demonstrated that the expression…
Abstract Number: 1793 • 2019 ACR/ARP Annual Meeting
Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Maxime Taghavi¹, Medha Barbhaiya ², Maria Tektonidou ³, Paul Fortin ⁴, Danieli Andrade ⁵, Jason Knight ⁶, Bahar Artim-Esen ⁷, Tatsuya Atsumi ⁸, Hannah Cohen ⁹, Lanlan Ji ¹⁰, Savino Sciascia ¹¹, Surya Seshan ¹², Doruk Erkan ¹³ and on Behalf of APS ACTION ¹⁴, ¹Brugmann Hospital, Brugmann, Belgium, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ⁵Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁶Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁷Istanbul University School of Medicine, Istanbul, Turkey, ⁸Hokkaido University, Sapporo, Japan, ⁹University College London, London, United Kingdom, ¹⁰Peking University First Hospital, Beijing, China (People's Republic), ¹¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ¹²Weill Cornell Medicine, New York, ¹³Hospital for Special Surgery, New York City, ¹⁴Hospital for Special Surgery, New York
Background/Purpose: Antiphospholipid antibody (aPL) nephropathy is a distinct entity that can be challenging to recognize and treat; it remains unknown if uniform pathologic criteria are…
Abstract Number: 126 • 2019 ACR/ARP Annual Meeting
Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS
Yann Becker¹, Anne-Sophie Julien ², Alexandra Godbout ³, Éric Boilard ³ and Paul Fortin ⁴, ¹Département de microbiologie et immunologie, Centre de recherche du CHU de Québec - Université Laval, Canada, Quebec, QC, Canada, ²Service de consultation statistique (SCS). Département de mathématiques et de statistique, Québec, QC, Canada, ³Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Québec, Qc, Canada, Québec, QC, Canada, ⁴Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada
Background/Purpose: Mitochondria are intracellular organelles involved in many biological pathways such as energy supply by oxidative phosphorylation and apoptosis. Mitochondria are considered as derived from…
Abstract Number: 1962 • 2019 ACR/ARP Annual Meeting
Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs
Markos Patsouras ¹, Panagiota Karagianni ¹, Marios Agelopoulos ², Spyros Foutadakis ², Eirini Alexopoulou ² and Panagiotis Vlachoyiannopoulos³, ¹Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece, Athens, ²Biomedical Research Foundation, Academy of Athens, ATHENS, ³University General Hospital of Athens “Laiko”, Athens, Greece
Background/Purpose: Antiphospholipid syndrome is an autoimmune thrombophillia characterized by recurrent thromboembolism and or pregrancy morbidity in the presence of antiphospholipid antibodies (aPL), which recognize either…
Abstract Number: 127 • 2019 ACR/ARP Annual Meeting
Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome
Hui Shi¹, Srilakshmi Yalavarthi ², Jianping Guo ³ and Jason Knight ⁴, ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), ⁴Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: The leukocyte immunoglobulin-like receptor A3 (LILRA3) gene encodes the only soluble receptor within the LILR family. LILRA3 polymorphisms have been associated with both rheumatoid…
Abstract Number: 128 • 2019 ACR/ARP Annual Meeting
Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis
Chun Li ¹, Yu Zuo², Jason Knight ³, Juan Feng ⁴, Xian Wang ⁴, David Karp ⁵ and Zhanguo Li ⁶, ¹Peking Univerisity People's Hospital, Beijing, China (People's Republic), ²University of Texas Southwestern, Dallas, TX, ³Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁴Peking University School of Basic Medical Science, Beijing, China (People's Republic), ⁵UTSouthwestern Medical Center, Dallas, TX, ⁶People's Hospital, Beijing University Medical School, Beijing, China (People's Republic)
Background/Purpose: The metabolic disturbances that underlie antiphospholipid syndrome (APS) are currently unknown. The goal of this study was to utilize high-throughput metabolomics screening to identify…
Abstract Number: 132 • 2019 ACR/ARP Annual Meeting
Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Chary Lopez-Pedrera¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Alejandro Ibañez-Costa ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Lourdes Alacaide-Ruggiero ⁵, Rafaela Ortega ¹, Nuria Barbarroja ⁶, Eduardo Collantes-Estevez ⁴, Massimo Radin ⁷, Irene Cecchi ⁷, Savino Sciascia ⁸ and Carlos Perez-Sanchez ⁹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba, Cordoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The clinical significance of non-canonical anti-phosphatidylserine/prothrombin (aPS/PT) antibodies in antiphospholipid syndrome (APS) is still controversial. This study assessed the prevalence of aPS/PT antibodies, their association with…
Abstract Number: 171 • 2018 ACR/ARHP Annual Meeting
Flow Cytometric Assessment of the Mammalian Target of Rapamycin Pathway Using Antiphospholipid Syndrome As a Disease Model
Ariel Badger¹, Ecem Sevim², Oral Alpan³ and Doruk Erkan⁴, ¹O&O Alpan Medical Center, Fairfax, VA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Allergy & Immunology, O&O Alpan Medical Center, Fairfax, VA, ⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: The mammalian target of rapamycin (mTOR) is a component of MTOR complex-1 that, when activated by upstream molecule protein kinase B (AKT) and another…
Abstract Number: 172 • 2018 ACR/ARHP Annual Meeting
Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study
Laura-Aline Martinez-Martinez¹, Fausto Sanchez-Muñoz², Maya Jazmin Nastia Nicte Chacon-Perez², Yaneli Juarez-Vicuña², Nicole Mouneu Ornelas¹, Anthony Beltran-Cortez², Ricardo Alberto Venegas Yañez³, Julio Fonseca Basurto¹, Evelyn Aranda Cano¹, Mary Carmen Amigo⁴ and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Reumatologia, Instituto Nacional de Cardiología "Ignacio Chavez", Ciudad de México, Mexico, ⁴Rheumatology, Centro Medico ABC, Mexico, Mexico
Background/Purpose: Recent evidence suggests that chemokines and miRNAs are involved in the pathogenesis of antiphospholipid syndrome (APS). However, the specific role of these molecules in…
Abstract Number: 174 • 2018 ACR/ARHP Annual Meeting
Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial
Josefina Cortés-Hernández¹, Luis Sáez-Comet², Antoni Riera Mestre³, A. Castro Salomó⁴, J. Cuquet Pedragosa⁵, Vera Ortiz-Santamaría⁶, M. Mauri Plana⁷ and Josep Ordi-Ros⁸, ¹Internal Medicine Department, Vall d´Hebron Hospital, Barcelona, Spain, ²Internal Medicine, Miguel Servet University Hospital, Zaragoza, Spain, ³VTE Unit. Internal Medicine, Bellvitge University Hospital, Barcelona, Spain, ⁴Hospital Universitari de Reus, Spain, Reus, Spain, ⁵Internal Medicine, Granollers University Hospital, Granollers, Spain, ⁶Rheumatology, Hospital General. Granollers., Granollers, Spain, ⁷Internal Medicine, Mataró Hospital, Mataró, Spain, ⁸Internal Medicine, Vall d'Hebron Hospital, Barcelona, Spain
Background/Purpose: Long-term anticoagulation with vitamin K antagonists (VKAs) is the standard of care in thrombotic antiphospholipid syndrome (APS) but requires frequent monitoring and dose adjustment.…
Abstract Number: 851 • 2018 ACR/ARHP Annual Meeting
Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Andrew Vreede², Omolola Eniola-Adefeso¹ and Jason S. Knight³, ¹University of Michigan, Ann Arbor, MI, ²Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³., University of Michigan, Ann Arbor, MI
Background/Purpose: While the role of antiphospholipid antibodies in activating endothelial cells has been extensively studied, the impact of these antibodies on the adhesive potential of…
Abstract Number: 856 • 2018 ACR/ARHP Annual Meeting
Integrated mRNA and microRNA Transcriptomes of Monocytes from Antiphospholipid Syndrome Patients Identifies Molecular Networks Related to Their Atherothrombotic Status. Modulatory Effects of In Vivo Ubiquinol Supplementation
Carlos Perez-Sanchez¹, Laura Pérez Sánchez², Alejandra Maria Patiño-Trives³, María Luque Tevar³, Luca Scudeler⁴, Alejandro Ibáñez-Costa³, Patricia Ruiz-Limon⁵, Yolanda Jiménez-Gómez¹, Ivan Arias de la Rosa⁶, Maria Carmen Abalos-Aguilera⁶, Pedro Segui⁷, Nuria Barbarroja¹, Jose Manuel Villalba⁸, Eduardo Collantes Estevez³, Maria Jose Cuadrado⁹, Maria Ángeles Aguirre Zamorano¹ and Chary Lopez-Pedrera³, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Università degli Studi di Torino, Turin, Italy, ⁵Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain., Málaga, MA, Spain, ⁶Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁷Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Departamento de Biologia Celular, Fisiologia e Inmunología, University of Córdoba, Cordoba, Spain, ⁹Clinica Universidad de Navarra, Madrid, Spain
Background/Purpose: 1. To characterize the mRNAs and microRNAs transcriptomes of monocytes, key immune cells in the atherothrombotic pathology of Antiphospholipid Syndrome patients (APS). 2. To…
Abstract Number: 1085 • 2018 ACR/ARHP Annual Meeting
Natural Gingerols Inhibit Neutrophil Extracellular Trap Release Elicited By Lupus Autoantibodies
Ramadan A. Ali¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Recent studies have revealed a role for neutrophils in the pathogenesis of lupus and antiphospholipid syndrome (APS). Indeed, neutrophils are activated by various disease-relevant…
Abstract Number: 1100 • 2018 ACR/ARHP Annual Meeting
The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Nuria Barbarroja², Patricia Ruiz-Limon³, Maria Carmen Abalos-Aguilera⁴, Yolanda Jiménez-Gómez², Ivan Arias de la Rosa⁴, Pedro Segui⁵, Rafaela Ortega-Castro², Eduardo Collantes Estevez¹, Alejandro Escudero-Contreras⁴, Lucas Le Lann⁶, Christophe Jamin⁶, Concepcion Marañón⁷, Marta Alarcón-Riquelme⁸, Jacques-Olivier Pers⁶ and Carlos Perez-Sanchez², ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain., Málaga, MA, Spain, ⁴Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁶U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ⁷GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain, ⁸Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: This study, developed within the IMI-JU project PRECISESADS framework, aimed to determine the enrichment on CD14+ and CD16+ monocyte subpopulations in SLE, APS and…
Abstract Number: 2137 • 2018 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
Cecilia Nalli¹, Greta Pascariello¹, Arianna Zentilin¹, Elena Raffetti², Laura Andreoli¹, Rajesh Kumar¹, Giuliana Martini³, Roberta Ottaviani¹, Cinzia Gasparotti⁴, Michele Magoni⁴, Carmelo Scarcella⁴, Francesco Donato⁵ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Epidemiology and Public Health Intervention Research group (EPHIR), Department of Public Health Sciences, Karolinska Institutet, Solna, Sweden, ³Hemostasis and Thrombosis Center, Spedali Civili of Brescia, Brescia, Italy, ⁴ATS Brescia (Brescia Health Protection Agency), Brescia, Italy, ⁵Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Unit of Hygiene, Epidemiology, and Public Health, University of Brescia, Italy., Brescia, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic autoimmune disease characterized by thrombotic and/or obstetrical manifestations mediated by antiphospholipid antibodies (aPL). By now, no population-based study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].